Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
Elutia Reports Q3 2026 Results: As Plastic Surgeons Cite Infection Risk at National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch